Full Press Release Details
Dr. Reddy s Laboratories (BSE: 500124, NSE:
DRREDDY, NYSE: RDY) will announce results for the Third Quarter and 9 months ended December 31, 2016 on Saturday, February 4, 2017 after the Board Meeting. The results will be available on the Company s website www.drreddys.com
| Event | Date and Time | Medium | ||
| Release of financial results | Feb 4 th , after the Board Meeting | Email, Media, Company website, Businesswire | ||
| Earnings Call | Feb 4 th , 6.30 PM IST / 8:00 AM EST | Hosted by the Company (Details below) | ||
| Webcast of Earnings Call | Feb 4 th , 6.30 PM IST / 8.00 AM EST through Feb 8 th | URL available on Company s website, www.drreddys.com | ||
| Transcript of the Earnings call | Will be available on the Company s website | URL available on Company s website, www.drreddys.com | ||
| Press meet presentation | Will be available on the Company s website | URL available on Company s website, www.drreddys.com |
the release, the management of the Company will host an earnings call to discuss the Company s financial performance. (Dial In and other details given below)
The audio webcast of the earnings call
will be available to all interested parties at www.drreddys.com. Please visit the web site at least fifteen minutes ahead of the scheduled start time to register and to download and install any necessary audio software. Participants in the
webcast can listen to the proceedings, but will not be able to ask questions. The replay will be available 2 hours after the earnings call, through Feb 8th, 2017. For play back dial in phone No:
022 3065 2322, 022 61813322 and ID: 375#.
| Conference Dial-In Numbers | ||
| Primary Number: | +91 22 3960 0616 | |
| The numbers listed above are universally accessible from all networks and all countries. | ||
| Local Access Number: | Accessible from all major carriers 3940 3977 Available in Ahmedabad, Bangalore, Chandigarh, Chennai, Kochi/Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Lucknow, Pune Accessible from all carriers. | |
| International Toll Free Number: | USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 |
No password/pin number is necessary to dial in to any of the other calls. As participation in the call is limited, early
registration is encouraged. The operator will provide instructions on asking questions before and during the call.
Dr. Reddy s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses
Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products Dr. Reddy s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and
differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy s operates in markets across the globe. Our major markets include
USA, Russia & CIS and India. For more information, log on to: www.drreddys.com
Disclaimer: This press release may include
statements of future expectations and other forward-looking statements that are based on the management s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events
to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words may , will , should , expects ,
plans , intends , anticipates , believes , estimates , predicts , potential , or continue and similar expressions identify forward-looking statements. Actual
results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates ,
persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the
policies of central banks and/or governments, (v) the impact of acquisitions or reorganisation , including related integration issues.
assumes no obligation to update any information contained herein.